Primary Description

Also known as:MOTS-cMitochondrial peptide MOTS-cMT-RNR1 peptideC101H152N28O22S2

MOTS-C is a 16-amino-acid peptide uniquely encoded by mitochondrial DNA (MT-RNR1 gene), making it one of the few peptides originating from the mitochondrial genome rather than the nuclear genome. It functions as an endogenous metabolic regulator and stress-response signaling molecule that mimics many molecular effects of exercise — earning it the label 'exercise mimetic.' Naturally released by mitochondria during cellular stress and physical exertion, MOTS-C activates AMPK, improves insulin sensitivity, promotes mitochondrial biogenesis, and declines with age by up to 21%. The longevity and biohacker community has embraced it as one of the most mechanistically compelling anti-aging peptides, despite no human clinical trials yet completed.

Key Benefits

Metabolic regulation
Exercise mimetic
Longevity

Storage & Stability

Lyophilized: stable at -20C long-term; stable at room temperature up to 3 weeks. Reconstituted: stable at 4C for up to 30 days with no significant degradation. Avoid repeated freeze-thaw cycles. For long-term reconstituted storage, add 0.1% BSA or HSA carrier protein.

Demonstrated Effects

AMPK activation — the master cellular energy sensor pathway triggered by exercise
Improved insulin sensitivity and glucose uptake in skeletal muscle
Mitochondrial biogenesis and enhanced oxidative phosphorylation capacity
Exercise mimetic effects — reproduces molecular signatures of physical training
Reversal of age-related skeletal muscle insulin resistance in preclinical models
Improved physical performance and endurance in aged animal models (young, middle-aged, and old mice)
Modulation of NAD+/NADH ratio supporting sirtuin activity and longevity pathways
Reduced visceral fat accumulation (preclinical: AMPK-mediated brown fat activation)
Anti-inflammatory effects via stress-response gene regulation

Proposed Mechanisms of Action

Proposed mechanisms based on available research

1. AMPK Activation

Description

MOTS-C activates AMP-activated protein kinase, the master cellular energy sensor. AMPK activation triggers increased glucose uptake into cells, enhanced fatty acid oxidation, improved mitochondrial biogenesis, and suppression of energy-consuming anabolic pathways — the same cascade activated by exercise and caloric restriction.

Practical Impact

Core driver of the exercise mimetic effect, insulin sensitization, fat oxidation, and metabolic benefits.

2. Mitochondrial-Nuclear Communication

Description

Under cellular stress, MOTS-C translocates from the mitochondrial/cytosolic compartment into the nucleus, where it directly regulates stress-adaptive gene programs including antioxidant response element (ARE) pathways. This retrograde mitochondrial-to-nuclear signaling is a unique feature not shared by nuclear-encoded peptides.

Practical Impact

Enables MOTS-C to coordinate a whole-cell adaptive response to metabolic stress, going beyond simple receptor signaling.

3. NAD+ / Sirtuin Pathway Modulation

Description

MOTS-C modulates the NAD+/NADH ratio by influencing the folate cycle and one-carbon metabolism. This supports sirtuin (SIRT1/SIRT3) enzymatic activity, which is central to longevity-related gene regulation, mitochondrial quality control, and circadian rhythm maintenance.

Practical Impact

Creates biochemical synergy with NAD+ precursors (NMN, NR) — MOTS-C creates demand for and supports NAD+-dependent pathways that NMN/NR feed.

Research Evidence & Clinical Data

Review of available research evidence and clinical data

Investigated Applications

Exercise Mimetic / Physical Performance

Anecdotal: Moderate

Community reports enhanced endurance, faster recovery, and improved training output. Users describe a noticeable increase in metabolic efficiency and reduced fatigue. Especially popular among older biohackers who report it partially compensates for age-related exercise capacity decline.

Preclinical basis: Skeletal muscle MOTS-C levels increase 11.9-fold in response to acute exercise (stationary bike, healthy young men). MOTS-C treatment significantly enhanced endurance in young, middle-aged, and old mice (Nature Communications, 2020).

Metabolic Health / Insulin Sensitivity

Anecdotal: Moderate

Community members with metabolic syndrome, insulin resistance, or prediabetes report improved fasting glucose and better post-meal glycemic response. Seen as complementary to GLP-1 agonists for metabolic optimization.

Preclinical basis: Ovariectomized female mice: 5 mg/kg MOTS-C i.p. for 5 weeks reduced fat accumulation and improved insulin sensitivity via AMPK-GLUT4 pathway. Systemic MOTS-C injection in aged mice reversed age-related skeletal muscle insulin resistance.

Longevity / Anti-Aging

Anecdotal: Emerging

The longevity community uses MOTS-C as a cornerstone of mitochondrial health protocols. The 21% age-related decline in circulating MOTS-C and the MOTS-C/longevity hypothesis for the Japanese population (who have favorable MOTS-C gene variants) have driven strong interest. Community members track biological age markers and cellular senescence indicators over multi-month MOTS-C protocols.

Preclinical basis: MOTS-C 15 mg/kg 3x/week in mice aged 23.5 months showed trend toward increased lifespan. Circulating MOTS-C ~21% lower in older adults. Japanese longevity associated with favorable MT-RNR1 gene variants encoding MOTS-C.

Scientific References

1.
Lee et al. (2015). MOTS-c: A mitochondrial-derived peptide regulating muscle and fat metabolism
Cell Metabolism2015
Discovery paper identifying MOTS-C as a mitochondrially-encoded peptide that activates AMPK, regulates insulin sensitivity, and promotes metabolic homeostasis.
2.
Reynolds et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis
Nature Communications2021
Demonstrates that MOTS-C declines with age, is induced 11.9-fold by exercise, and that exogenous MOTS-C administration significantly improves physical performance in young, middle-aged, and old mice.

Safety Profile

Common Side Effects

Injection site reactions — most notable side effect; nodules or persistent local reactions common, especially with repeated injections at same site
Short half-life may require frequent injections limiting long-term tolerability
No established human safety database; all known side effects from short-term animal studies or anecdotal community reports
Potential fatigue during initial high-dose use (loading phase)
CB4211 (MOTS-C analogue) Phase I data: persistent injection site reactions common but otherwise safe at short-term evaluation
Minimal reported

Contraindications

No established absolute contraindications (insufficient human safety data to define)
Pregnancy and breastfeeding — no safety data; avoid
Active cancer — theoretical concern: AMPK activation and metabolic modulation could theoretically affect tumor metabolism; use not recommended without oncology input
WADA-prohibited athletes — explicitly banned since 2024
None well-established

Pre-Use Screening Checklist

Metabolic baselineOptional

Fasting glucose, HbA1c, and metabolic panel useful to establish baseline and track MOTS-C metabolic effects objectively.

Active cancerDo NOT use

AMPK signaling has complex cancer biology implications — can be both tumor-suppressive and tumor-promoting depending on context. No data to guide safe use in active malignancy.

Competitive athletes (anti-doping)Do NOT use

MOTS-C is explicitly prohibited by WADA since 2024 in the S4 category (hormone and metabolic modulators).

Legal & Regulatory Status

FDA

Not approved. No human clinical trials registered. Research compound only.

WADA

PROHIBITED — explicitly listed on WADA Prohibited List since 2024 under S4 (Hormone and Metabolic Modulators).

MEXICO

Not approved by COFEPRIS. Available as research peptide. No specific regulatory guidance.

EU

Not approved by EMA. Research compound status.

AUSTRALIA

Not approved by TGA. Research compound only.

Research Protocols

Dosing protocols based on available research data

Dosing Protocols

Standard metabolic/performance protocol

Subcutaneous (abdomen or thigh)

Dose

5 mgmg

Frequency

2-3 times per week, subcutaneous injection

Duration

—

Route

Subcutaneous (abdomen or thigh)

Note: Optional 5-7 day loading phase at 5 mg daily, then reduce to 2-3x weekly. Cycle 8-12 weeks on, 4 weeks off. Many community members prefer training-day dosing. Inject 30-60 min before exercise for potential performance timing benefit.

Longevity / anti-aging maintenance

Subcutaneous

Dose

5-10 mgmg

Frequency

2-3 times per week, year-round with periodic breaks

Duration

—

Route

Subcutaneous

Note: Some longevity-focused community members dose 10 mg 3x/week extrapolating from preclinical dosing ratios. No human data at 10 mg 3x/week. Start at 5 mg 2x/week and assess tolerance. Persistent injection site nodules are common — rotate sites.

Routes of Administration

Subcutaneous injection

Most common

Standard route for research use. Injected into lower abdominal fat, thigh, or upper arm with insulin syringe. Short half-life and poor oral bioavailability make injection the only viable route.

Injection site nodules reported more commonly than with other peptides. Rotate sites with each injection. Use 29-31 gauge 0.5 inch needle at 45 degree angle.

Reconstitution Guide

Solvent / Vehicle

Sterile water (18 MOhm, endotoxin-free) or bacteriostatic water. Sterile saline also acceptable.

Process

1. Allow vial to reach room temperature. 2. Clean septum with alcohol. 3. Slowly inject solvent down the vial wall. 4. Gently swirl to dissolve — do NOT shake. 5. Solution should be clear and colorless. 6. Label with date.

Concentration

For 10 mg vial with 2 mL bacteriostatic water = 5 mg/mL. To dose 5 mg: draw 1 mL (100 units on U100 insulin syringe). To dose 2.5 mg: draw 0.5 mL.

Storage (Reconstituted)

Refrigerate at 4C. Stable up to 30 days. For longer storage, aliquot and freeze at -20C. Add 0.1% BSA/HSA if storing beyond 7 days.

Storage (Lyophilized)

Store at -20C or lower for long-term. Stable at room temperature up to 3 weeks. Desiccated, protect from moisture and light. Avoid freeze-thaw cycles.

Timing Notes

Community preference for training-day injections 30-60 minutes pre-exercise for potential synergy with exercise-induced AMPK activation. Morning dosing favored for longevity protocols.

Pharmacokinetics

Half-Life	Short biological half-life; exact value in humans not yet established. Preclinical data suggests rapid clearance requiring dosing 2-3x per week for sustained effect. CB4211 (analogue) demonstrated improved stability over native MOTS-C.
Absorption	Poor oral bioavailability due to peptide degradation in GI tract. Subcutaneous injection provides direct systemic absorption. Tendency to persist at injection site (contributes to injection site nodules).
Distribution	Distributed to skeletal muscle, liver, adipose tissue, and potentially nucleus under stress conditions. In vivo, MOTS-C translocates from cytoplasm to nucleus during metabolic stress.
Metabolism	Metabolized via proteolysis. Short half-life limits duration of action and is a key challenge for clinical development.
Molecular Structure	16-amino-acid peptide: MRWQEMGYIFYPRKLR. MW 2174.64 g/mol. CAS 1627580-64-6. Encoded by mitochondrial MT-RNR1 gene within 12S rRNA sequence.

Monitoring & Risk Management

Monitoring guidelines based on available data

Ongoing Monitoring Steps

Injection site assessmentNodules, persistent induration, redness, warmth. Rotate sites consistently.Check: Each injection
Metabolic markersFasting glucose, insulin, HbA1c to track insulin sensitivity improvements. Lipid panel.Check: Every 8-12 weeks
Performance markersStandardized physical performance tests (VO2, strength, endurance benchmarks) to objectively track exercise mimetic effects.Check: Monthly

Critical Warning Signs

Persistent, enlarging, or painful injection site noduleDiscontinue injections at that site. Assess for abscess or sterile lipogranuloma. Rotate to new sites. If warm, fluctuant, or spreading redness, seek medical evaluation for infection.Urgency: Within 1 week if persistent
Hypoglycemic symptoms in diabetics or those on insulin/secretagoguesMOTS-C improves insulin sensitivity and could potentiate hypoglycemia in those on antidiabetic medications. Reduce secretagogue or insulin doses and monitor CGM closely.Urgency: IMMEDIATE

Health & Research Goals

MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA-c)